Selzentry Advisory Committee To Weigh Virologic Resistance Vs. Adverse Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer wants to expand the indication of its HIV drug to treatment-naive patients, but FDA wants the panel's advice on what the standards for such a claim should be.